MNG1101
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.300
- MYOGENESIS+0.298
- KRAS_SIGNALING_DN+0.286
- APICAL_SURFACE+0.217
- ANGIOGENESIS+0.188
- COAGULATION+0.160
- ESTROGEN_RESPONSE_LATE+0.067
- P53_PATHWAY+0.058
- APICAL_JUNCTION+0.047
- SPERMATOGENESIS+0.042
Top 10 suppressed
- UNFOLDED_PROTEIN_RESPONSE-0.544
- MYC_TARGETS_V1-0.512
- TGF_BETA_SIGNALING-0.459
- PROTEIN_SECRETION-0.453
- MTORC1_SIGNALING-0.446
- G2M_CHECKPOINT-0.425
- MITOTIC_SPINDLE-0.425
- MYC_TARGETS_V2-0.424
- ANDROGEN_RESPONSE-0.422
- INTERFERON_ALPHA_RESPONSE-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CF-A3MI-01A-11R-A20F-07 | — | — | 0.948 |
| 2 | MNG923 | — | — | 0.936 |
| 3 | SRR1500405 | GTEX | — | 0.935 |
| 4 | MNG771 | — | — | 0.934 |
| 5 | SRR1340301 | GTEX | — | 0.931 |
| 6 | BS_23W9EPFE | Ganglioglioma | — | 0.930 |
| 7 | MNG1259 | — | — | 0.929 |
| 8 | MNG436 | — | — | 0.925 |
| 9 | MDT-AP-1190 | Med | Medulloblastoma | 0.924 |
| 10 | SRR1442195 | GTEX | — | 0.922 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.298 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.286 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.217 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.188 | Remibrutinib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.067 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.058 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.047 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.042 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.017 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.014 | Inavolisib | — uncovered |